Abstract
Clozapine is the best treatment option in several clinical circumstances, including treatment-resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinsons disease, prevention and treatment of tardive dyskinesia. However, clozapine is associated with many serious side effects. Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage clozapine use. Therefore, the drug is underused. The only way to avoid the underuse of clozapine is full awareness of its side effects and competence to minimize them. The aim of the paper is reviewing the safety profile of clozapine and the suggested strategies in the management of its side effects, including neutropenia, eosinophilia, seizures, myocarditis, weight gain, diabetes, metabolic syndrome, hypersalivation, fever, constipation, ileus, urinary incontinence, sweating. The neuropsychiatric side effects of clozapine are not discussed in this review.
Keywords: Clozapine, schizophrenia, side effects, treatment
Current Drug Safety
Title: Clozapine Safety, 35 Years Later
Volume: 6 Issue: 3
Author(s): Michele Raja
Affiliation:
Keywords: Clozapine, schizophrenia, side effects, treatment
Abstract: Clozapine is the best treatment option in several clinical circumstances, including treatment-resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinsons disease, prevention and treatment of tardive dyskinesia. However, clozapine is associated with many serious side effects. Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage clozapine use. Therefore, the drug is underused. The only way to avoid the underuse of clozapine is full awareness of its side effects and competence to minimize them. The aim of the paper is reviewing the safety profile of clozapine and the suggested strategies in the management of its side effects, including neutropenia, eosinophilia, seizures, myocarditis, weight gain, diabetes, metabolic syndrome, hypersalivation, fever, constipation, ileus, urinary incontinence, sweating. The neuropsychiatric side effects of clozapine are not discussed in this review.
Export Options
About this article
Cite this article as:
Raja Michele, Clozapine Safety, 35 Years Later, Current Drug Safety 2011; 6 (3) . https://dx.doi.org/10.2174/157488611797579230
DOI https://dx.doi.org/10.2174/157488611797579230 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Current Clinical Pharmacology New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents